Below is a short summary and detailed review of this video written by FutureFactual:
The Rest Is Science: Cancer Research UK Cancan Team Cachexia Autopsy Insights and Lung Cancer Vaccines
Episode snapshot
In this Rest Is Science episode, hosts engage with Professor Mariam Jamal-Hanjani to discuss Cancer Research UKs Cancan program, the biology of cachexia, and innovative approaches to lung cancer including autopsy-derived insights and vaccine strategies. The conversation emphasizes collaboration, patient involvement, and a hopeful path forward in cancer research.
- The episode centers on cancer complexity and collaborative solutions
- Cachexia as a major, poorly understood syndrome in advanced cancer
- Autopsy studies illuminate cancer spread and inform early detection strategies
- Vaccine approaches like lungvax aim to prevent recurrence and potentially new cancers
Introduction and guest
This podcast episode features The Rest Is Science hosts in conversation with Professor Mariam Jamal-Hanjani, a leader in lung cancer research and Cancer Research UKs chief clinician. The discussion covers the alliance with Cancer Research UK, the breadth of research topics explored over the past year, and the teams efforts to translate complex science into narratives that educate and inspire the public. The tone is forward-looking, emphasizing hope and collective action in the fight against cancer.
From physics to medicine and the work in lung cancer
Mariam shares her journey from a physics-influenced mindset to medicine, motivated by a desire to impact human health and to understand how to heal. She explains how precision medicine has transformed lung cancer treatment by enabling targeted therapies and immunotherapies, and how combinations with chemotherapy and radiotherapy are expanding options for patients. The conversation also touches on public misconceptions about lung cancer cause, noting the roles of smoking, air pollution, and environmental exposures in disease risk. The host and guest discuss the evolving questions in cancer research, including who gets cancer, why it arises, how it spreads, and how the body and tumors interact with the immune system.
The complexity of cancer and cachexia
A major portion of the discussion centers on cachexia, a wasting syndrome that affects a large fraction of patients with advanced cancer. The speakers outline how cachexia goes beyond simple weight loss, involving disruptions to appetite regulation, energy metabolism, and muscle and fat tissue turnover. They explain that even with increased caloric intake, metabolic signals can drive ongoing tissue loss, and that cachexia can be life-limiting due to weakness of respiratory and cardiac muscles. The Cancan team is highlighted for its multidisciplinary approach to unraveling the biology of cachexia and identifying therapeutic targets. The goal is to detect signals early and to develop interventions that prevent or mitigate cachexia rather than merely reacting to its progression.
Clinical translation and ongoing trials
The discussion shifts to how researchers translate mechanistic insights into therapies. The team points to a growing set of clinical trials targeting various molecular pathways linked to cachexia, including strategies to preserve muscle mass and stabilize weight. They also discuss GDF15 as a regulator of appetite and a target for intervention, along with the complexity of targeting multiple signals due to the integrated nature of metabolism, immunity, and neurobiology. The interview emphasizes that while progress is being made, there is no single magic bullet; progress comes from a portfolio of approaches evaluated in diverse patient populations.
Autopsy studies and understanding metastasis
The Peace Research Autopsy Study is introduced as a national UK effort that collects tissues after patients pass away, with consent, to understand how cancers originate, evolve, and metastasize. The autopsy resource helps researchers map cancer spread across organs and to retrospectively link genetic changes in advanced disease with early blood-based signals. This work is complemented by tracer studies that track tumor evolution in the bloodstream, enabling the detection of metastatic signals months before they appear on scans. Mariam explains how these insights can refine when and how to intervene in disease progression.
Early prevention and vaccines
The lungs vaccine concept, Lungvax, is presented as a first-in-human trial designed to prime immune recognition of tumor-associated antigens, with potential for primary prevention in high-risk individuals and prevention of relapse in patients in remission after surgery. The discussion recognizes that vaccines aimed at cancer prevention could redefine long-term cancer control if safety and efficacy thresholds are met. The hosts are careful to frame vaccine research as part of a broader strategy that includes early detection, risk reduction, and combination therapies.
Emerging biology and broader horizons
Mariams remarks cover extrachromosomal DNA, or ecDNA, a rogue genetic material found in some aggressive cancers that carries oncogenes and can sustain tumor growth. The conversation outlines how ecDNA can be targeted to disrupt tumor progression and how therapies could be tailored to tumors that harbor ecDNA. The potential applications span multiple cancer types including brain, lung, breast, ovarian, colorectal and gastric cancers. The dialogue also notes the broader research program that spans immunology, metabolic regulation, neurobiology, and cancer evolution, all under Cancer Research UK's umbrella and powered by interdisciplinary collaboration.
Optimism and the patient voice
The episode closes with reflections on the patients and volunteers who fuel cancer research. The speakers emphasize the importance of hope and community engagement in sustaining long-term scientific progress. They acknowledge that while the path is challenging, the current era represents a golden age of cancer research, driven by collaboration, patient involvement, and bold, long-term thinking. The message to listeners is clear hope coupled with action, inviting continued support for cancer research as a legacy for patients and volunteers alike.



